本頁面由Tiger Trade Technology Pte. Ltd.提供服務

Immunovant, Inc.

39.41
+0.04000.10%
盤後39.410.00000.00%19:34 EDT
成交量:72.71萬
成交額:2,862.00萬
市值:80.91億
市盈率:-14.22
高:39.87
開:39.80
低:38.70
收:39.37
52周最高:41.23
52周最低:14.32
股本:2.05億
流通股本:7,983.12萬
量比:0.82
換手率:0.91%
股息:- -
股息率:- -
每股收益(TTM):-2.7716
每股收益(LYR):-2.7716
淨資產收益率:-64.82%
總資產收益率:-38.43%
市淨率:9.49
市盈率(LYR):-14.22

資料載入中...

公司資料

公司名字:
Immunovant, Inc.
交易所:
NASDAQ
成立時間:
2018
員工人數:
315
公司地址:
1000 Park Forty Plaza,Suite 210,Durham,North Carolina,United States
郵編:
27713
電話:
傳真:
- -
簡介:
Immunovant, Inc.於2018年12月6日在特拉華州註冊成立,是一家臨床階段的免疫學企業,專註於開發自身免疫性疾病的治療方法。主要推進FCRN抑製劑IMVT-1402靶向由致病性IgG抗體引發的自身免疫性疾病,此前還開發了另一種抗FCRN抗體batoclimab。該公司對其主要候選藥物進行跨越內分泌學、神經病學、風濕病學和皮膚病學等多個疾病領域的臨床研究,與HanAll合作設計高效抗-FCRN抗體,並已停止batoclimab的進一步開發以全面專註於IMVT-1402的臨床進展,將batoclimab項目的試驗運營經驗和臨床見解應用於其核心產品開發。

董事

名稱
職位
Eric Venker
Chief Executive Officer and Director
Andrew Fromkin
Independent Director
Atul Pande
Independent Director
Douglas Hughes
Independent Director
Frank M. Torti
Director and Executive Chairperson of the Board
Jacob Bauer
Independent Director
Robert Susman
Independent Director

股東

名稱
職位
Eric Venker
Chief Executive Officer and Director
Melanie Gloria
Chief Operating Officer
Tiago Girão
Chief Financial Officer
Christopher Van Tuyl
Chief Legal Officer and Corporate Secretary
Frank M. Torti
Director and Executive Chairperson of the Board
Jay S. Stout
Chief Technology Officer